As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
10 Analysts have issued a Poseida Therapeutics Inc forecast:
10 Analysts have issued a Poseida Therapeutics Inc forecast:
| Sep '24 |
+/-
%
|
||
| Revenue | 151 151 |
203%
203%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -57 -57 |
57%
57%
|
|
| EBIT (Operating Income) EBIT | -63 -63 |
54%
54%
|
|
| Net Profit | -61 -61 |
54%
54%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Kristin Yarema |
| Employees | 350 |
| Founded | 2014 |
| Website | poseida.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


